QPS cardiac collaboration to extend sponsor networks

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/AlexRaths)
(Image: iStock/AlexRaths)

Related tags: Pharmacology, Medicine

QPS Holdings LLC and G-CURE BV will collaborate on cardiovascular drug development programs for pharmaceutical companies.

Per the collaboration, preclinical research will be carried out by G-CURE at the University Medical Center Groningen (UMCG) experimental cardiology laboratory. QPS will work from its preclinical ADME laboratories in Newark, Delaware and/or its fully GLP compliant toxicology laboratories in Taipei, Taiwan.

By joining forces we both expect to be able to extend our sponsor networks​,” Ben Chien, CEO of QPS Holdings, LLC told Outsourcing-Pharma.com. “Second, we are unique in our set-up in which we can do both healthy volunteer and cardiac patient studies in one setting​.”

According to the company, the three preclinical testing facilities will provide a “broad technical platform​” to speed early development.

Together, we hope to be at the forefront of the development of innovative cardiac drugs that will hopefully ultimately improve the lives of patients suffering from cardiac diseases​,” said Chien.

The next step will be to explore each other’s network and actively look for early cardiac drug development programs that we can execute together​.”  

Related topics: Preclinical Research, Preclinical

Related news

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us


View more